Cytokinetics Reports Third-Quarter Revenue of $47.6 Million
Story updates
09:00:23 PM UTC
SquawkNews
MYQORZO® (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Afic
09:03:36 PM UTC
SquawkNews
*-- Earnings Flash (CYTK) Cytokinetics, Incorporated Reports Q3 Revenue $47.6M, vs. FactSet Est of $41.9M
09:15:12 PM UTC
SquawkNews
Cytokinetics reported third-quarter 2026 revenue of $47.6 million, including $44.5 million in MYQORZO sales, and a net loss of $190.1 million. The company ended September with approximately $1.6 billion in cash, cash equivalents and investments. It reaffirmed its full-year 2026 expense guidance and…
09:42:16 PM UTC
SquawkNews
Cytokinetics reported third-quarter 2026 revenue of $47.6 million, up from $1.9 million a year earlier, as MYQORZO generated $44.5 million in product revenue. The company recorded a net loss of $190.1 million, or $1.37 per diluted share, compared with a $306.2 million loss, or $2.55 per diluted sha…